Cariprazine, a dopamine D 3 /D 2 receptor partial agonist with preference for D 3 receptors, has demonstrated efficacy in randomized controlled trials in schizophrenia. This multinational, randomized, double-blind, placebo-controlled, parallel-group study evaluated the efficacy, safety, and tolerability of cariprazine for relapse prevention in adults with schizophrenia; total study duration was up to 97 weeks. Schizophrenia symptoms were treated/stabilized with cariprazine 3-9 mg/d during 20-week open-label treatment consisting of an 8-week, flexible-dose run-in phase and a 12-week fixed-dose stabilization phase. Stable patients who completed open-label treatment could be randomized to continued cariprazine (3, 6, or 9 mg/d) or placebo for double-blind treatment (up to 72 weeks). The primary efficacy parameter was time to relapse (worsening of symptom scores, psychiatric hospitalization, aggressive/violent behavior, or suicidal risk); clinical measures were implemented to ensure safety in case of impending relapse. A total of 264/765 patients completed openlabel treatment; 200 eligible patients were randomized to double-blind placebo (n = 99) or cariprazine (n = 101). Time to relapse was significantly longer in cariprazine-versus placebo-treated patients (P = .0010, logrank test). Relapse occurred in 24.8% of cariprazine-and 47.5% of placebo-treated patients (hazard ratio [95% CI] = 0.45 [0.28, 0.73]). Akathisia (19.2%), insomnia (14.4%), and headache (12.0%) were reported in ≥10% of patients during open-label treatment; there were no cariprazine adverse events ≥10% during double-blind treatment. Long-term cariprazine treatment was significantly more effective than placebo for relapse prevention in patients with schizophrenia. The long-term safety profile in this study was consistent with the safety profile observed in previous cariprazine clinical trials. ClincalTrials.gov identifier: NCT01412060.
Introduction
Schizophrenia is a serious neuropsychiatric syndrome that often has a severe and chronic course (Emsley et al., 2013) ; it substantially contributes to the burden of disease attributable to mental health disorders globally (Whiteford et al., 2013) . Relapses in schizophrenia are common, with each subsequent event contributing to clinical deterioration including worsening of symptoms, cognitive impairment, reduced social and vocational functioning, and diminished quality of life (Fleischhacker et al., 2014; Lehman et al., 2004; Olivares et al., 2013; Taylor et al., 2005) . Although long-term antipsychotic treatment may substantially reduce relapse risk in the stable phase of schizophrenia (Kane, 2007) , partial or total nonadherence to medication is a ubiquitous clinical problem (Leucht and Heres, 2006; Morken et al., 2008) . Prevention of relapse is an integral component of comprehensive schizophrenia management.
Cariprazine is a dopamine D 3 and D 2 receptor partial agonist antipsychotic with preferential binding to D 3 receptors (Kiss et al., 2010) . Unlike other new generation antipsychotics, which display high occupancy at D 2 receptors but low or negligible occupancy at D 3 receptors (Graff-Guerrero et al., 2009; Gyertyán et al., 2011; Mizrahi et al., 2011) , cariprazine shows high and balanced occupancy of D 3 and D 2 receptors at doses effective for the treatment of psychosis (Gyertyán et al., 2011; Kiss et al., 2010) . This pharmacological profile may provide benefits in treating cognitive impairment, negative symptoms, and mood symptoms associated with schizophrenia Laszy et al., 2005; Schwartz et al., 2000) . Cariprazine also has a unique pharmacokinetic profile, with 2 major active metabolites, desmethyl cariprazine and didesmethyl cariprazine. The effective halflife for the total active moieties, which takes into account cariprazine and the 2 major active metabolites, is approximately 1 week (Nakamura et al., 2016) . This long half-life may confer some continued effect after drug discontinuation, perhaps providing protection against rapid onset of relapse in cases of nonadherence. The efficacy and safety of cariprazine in patients with schizophrenia have been supported in 3 positive randomized, placebo-controlled, phase II/III clinical studies (Durgam et al., 2014 Kane et al., 2015) . The current study was designed to assess the efficacy, safety, and tolerability of long-term treatment with cariprazine for preventing symptomatic relapse in patients with schizophrenia (ClinicalTrials.gov. NCT01412060).
Patients and methods
This study was conducted from 2011 to 2014 in 72 centers (United States, India, Romania, Slovakia, and Ukraine) in accordance with the Declaration of Helsinki and ICH Guidance. Sites obtained institutional review board (US centers) or ethics committee/government agency (non-US centers) approval before the study. All participants provided written informed consent.
To identify early signs of relapse and ensure patient safety in the event of relapse, patients were required to have up to 2 consented caregivers who also assisted with hospitalization discharges, medication compliance, and study visits. Unscheduled study visits could be arranged in cases of potential relapse.
Study design
This study consisted of 5 phases (screening, open-label run-in, openlabel stabilization, double-blind treatment, safety follow-up) with a total duration up to 97 weeks; dosing was flexible (cariprazine 3-9 mg/d) or fixed (cariprazine 3, 6, or 9 mg/d) depending on the study phase (Fig. 1 ). Patients were required to complete the prior study phase and meet all of the following eligibility criteria to progress from open-label run-in to open-label stabilization (end of week 8) and from open-label stabilization to double-blind treatment (end of week 20): Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) total score ≤ 60; at least 20% decrease in PANSS total score from baseline; Clinical Global Impressions-Severity of Illness (CGI-S) (Guy, 1976b) score ≤ 4; score ≤ 4 on each of 7 PANSS items (delusions, conceptual disorganization, hallucinatory behavior, suspiciousness/persecution, hostility, uncooperativeness, and poor impulse control); and no significant tolerability issues (investigator judged). Patients who did not meet eligibility criteria at the end of each open-label phase were discontinued from the study and seen for a final/early termination visit.
Patients were hospitalized during screening and for the first 2 weeks of the run-in phase; they were then either discharged and followed-up as outpatients, or hospitalized for 2 additional weeks (investigator discretion). Patients unable to be discharged after 4 weeks were discontinued due to insufficient therapeutic response or unavailability of a caregiver.
Patients were randomized (1:1) to fixed-dose cariprazine or placebo for double-blind treatment of variable duration (26-72 weeks or until early termination including a relapse event) (Fig. 1) . Per protocol, double-blind treatment for all active patients was stopped when the last randomized patient completed 26 weeks of treatment regardless of the number of relapse events. Investigators and patients were blinded to the double-blind treatment assignment through an interactive web response system; identically appearing treatments were used. Breaking the randomization code disqualified the patient from further participation.
Patients
To be included, male or female inpatients (18-60 years of age, inclusive) were required to have a current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) (American Psychiatric Association, 2000) diagnosis of schizophrenia (minimum 1 year) and a current psychotic episode b 4 weeks' duration. Patients additionally had a PANSS total score ≥ 70 and ≤120, and a score ≥ 4 (moderately severe) on at least 2 PANSS positive symptoms (delusions, hallucinatory behavior, conceptual disorganization, suspiciousness/persecution). Patients in their first psychotic episode were excluded; various psychiatric conditions other than schizophrenia or concurrent medical conditions that could interfere with study conduct, confound interpretation of results, or endanger patient well-being were also exclusionary. Additional exclusion criteria are presented in Table S1 .
Efficacy assessments
The primary efficacy parameter was time to first relapse during double-blind treatment (number of days from randomization to the relapse date); patients who did not meet relapse criteria were considered censored at the time of completion or discontinuation from the study. Patients who completed open-label treatment and met eligibility criteria after each phase were randomized (1:1) to double-blind treatment. Cariprazine was initiated at 1.5 mg/d and increased to 3.0 mg/d on day 2; for patients with inadequate response and no significant tolerability issues (investigator judged), dosage increases were allowed on day 6 (6.0 mg/d [interim increase to 4.5 mg/d on day 4]) and day 10 (9.0 mg/d) if needed. Flexible-dose cariprazine 3-9 mg/d was continued through week 6 of the run-in phase; fixed-dose cariprazine 3, 6, or 9 mg/d (no adjustments allowed) was administered for weeks 7 and 8. During the open-label stabilization phase, cariprazine was continued at the same fixed dose as in the last 2 weeks of the run-in phase; dose decreases to 3 or 6 mg/d were allowed for significant tolerability issues. During double-blind treatment, cariprazine was administered at the same fixed dose as in the stabilization phase but no adjustments were allowed. During the safety follow-up, patients continued as outpatients and received treatment as usual at the discretion of the investigator; patients did not receive study drug.
Relapse was defined by objective rating scale criteria and subjective clinical measures (Table 1) ; patients meeting any relapse criterion were discontinued from the study. There was no prespecified secondary efficacy parameter. Additional efficacy parameters and safety assessments are presented in Table 1 . The primary efficacy analysis compared time to relapse between placebo and cariprazine using the log-rank test. Hazard ratio (HR) estimates and 95% confidence interval (CI) were based on the Cox proportional hazards model with treatment group as an explanatory variable. The cumulative distribution function of time to relapse was estimated by Kaplan-Meier curves. Additional efficacy parameters were analyzed descriptively in the open-label and double-blind ITT populations; missing values were imputed separately for each study phase using a last observation carried forward (LOCF) approach.
Statistical analyses
It was estimated that~80 total relapse events needed to be observed during the double-blind phase, including both cariprazine and placebo groups, to have 90% power to detect a statistically significant difference between cariprazine and placebo with a hazard ratio of 0.48 at an overall 5% level of significance and that 180 randomized patients (~90 per treatment group) in double-blind treatment would have provided the required total number of relapse events.
Results

Patient disposition
Patient disposition and reasons for study withdrawal are presented in Fig. 2 . During open-label treatment, the most common reason for discontinuation was withdrawal of consent (~20%). When queried to ensure that AEs were not the reason for discontinuation, some patients indicated that they were unable to continue due to the length of the study (up to 92-weeks) and the time commitment involved. During double-blind treatment, per protocol discontinuation (i.e., once the last randomized patient completed 26 weeks of double-blind treatment, double-blind treatment was stopped for all active patients per protocol) was the most common reason for discontinuation (cariprazine = 20.8%; placebo = 9.1%) other than relapse. Most demographic characteristics were similar among groups; a statistically significant difference between groups was observed in the distribution of males and females in the double-blind phase (Table 2) .
Efficacy analyses
Time to relapse was significantly longer for cariprazine versus placebo (Fig. 3) . Overall, relapse occurred in 47.5% (47/99) of placebo-and 24.8% (25/101) of cariprazine-treated patients. The hazard of relapse for cariprazine-treated patients was estimated to be less than half that of placebo-treated patients (HR [95% CI] = 0. 45 [0.28, 0.73] ). The most commonly met relapse criteria in the placebo-and cariprazine-treatment groups, respectively, were increase in PANSS score (43.4% and 20.8%), increase in CGI-S (28.3% and 4.0%), and score ≥ 4 on any of the assessed PANSS items (25.3% and 10.9%). The psychiatric hospitalization criterion was met by 9.1% and 8.9% of placebo-and cariprazine-treated patients, respectively. Relapse rates at weeks 2, 4, and 6, respectively, were similar for placebo-treated patients ( At the end of open-label treatment, mean improvements in PANSS total and subscale scores, CGI-S, NSA-16 total, and PSP scores were observed; at the end of double-blind treatment, scores on these scales worsened to a greater extent for placebo-treated patients than for cariprazine-treated patients (Table 3) . Table 1 Relapse criteria, additional efficacy parameters, and safety assessments.
Relapse criteria (meeting any 1 of the relapse criteria was considered a relapse) Rating scale criteria (confirmed at a repeat visit within 7 days at the investigator's discretion):
Increase ≥30% in PANSS total score for patients who scored ≥50 at randomization or a ≥10-point increase for patients who scored b50 at randomization Score N 4 on any of the 7 PANSS items assessed at randomization (delusions, conceptual disorganization, hallucinatory behavior, suspiciousness/persecution, hostility, uncooperativeness, poor impulse control) CGI-S score increase ≥ 2 points from randomization Clinical relapse criteria (investigator judged):
Psychiatric (Guy, 1976a) ; BARS, Barnes Akathisia Rating Scale (Barnes, 1989) ; CGI-I, Clinical Global Impressions-Improvement (Guy, 1976b) ; CGI-S, Clinical Global Impressions-Severity; C-SSRS, Columbia-Suicide Severity Rating Scale (Posner et al., 2011) 3.3. Safety 3.3.1. Extent of exposure Mean (SD) duration of cariprazine exposure was 75.7 (54.2) days and 257 (184.0) days in the open-label and double-blind safety populations, respectively; mean duration of placebo exposure was 205.9 (176.7) days. At randomization, 14 patients were taking cariprazine 3 mg/d, 37 patients were taking 6 mg/d, and 50 patients were taking 9 mg/d.
Adverse events
An overall summary of AEs is presented in Table 4 . Treatment-emergent AEs (TEAEs) that occurred in ≥10% of patients during open-label treatment were akathisia, headache, and insomnia; during double- blind treatment, tremor and back pain were the only TEAEs reported in ≥5% of cariprazine patients and at an incidence at least twice that of placebo. The incidence of akathisia, the most common open-label TEAE, was higher during the run-in phase (18.6%) than in the stabilization phase (6%) or double-blind treatment (placebo = 3%; cariprazine = 5%). Greater than 98% of akathisia was considered mild or moderate. The overall incidence of EPS TEAEs (excluding akathisia and restlessness) was 19.7% during open-label treatment, and 3% and 15.8% for placebo-and cariprazine-treated patients, respectively, during doubleblind treatment. Worsening of schizophrenia was the only AE leading to the discontinuation of ≥2% of patients during the open-label (3.0%) and doubleblind (placebo, 9.1%; cariprazine, 5.9%) phases. During open-label treatment, akathisia and other EPS AEs (excluding akathisia or restlessness) each led to discontinuation in approximately 1% of patients; no EPS-related AEs led to discontinuation during double-blind treatment. TEAEs were considered related to treatment in 60.5% and 44.6% of cariprazine-treated patients during open-label and double-blind treatment, respectively, and in 32.3% of placebo-treated patients during double-blind treatment. Most double-blind TEAEs were considered mild or moderate in severity (placebo = 95.4%; cariprazine = 95.7%).
The only serious AE (SAE) reported in ≥2% of patients during openlabel treatment was worsening of schizophrenia (2.9%); during double-blind treatment, SAEs reported in ≥2% of patients in either the placebo-or cariprazine-treatment groups, respectively, were worsening of schizophrenia (7.1% and 6.9%), and psychotic disorder (2.0% and 2.0%). All other SAEs reported during the study were reported in ≤ 1% of patients.
A summary of laboratory values and significant treatment-emergent changes in lipids and glucose are presented in Tables S2 and S3 . Mean changes from baseline in lipid parameters at the end of the open-label and double-blind treatment were generally not clinically relevant. There were no clinically relevant mean changes in blood pressure and no patient had QTcF or QTcB N 500 ms during the study. The incidence of orthostatic hypotension (decrease ≥20 mm Hg in systolic blood pressure or decrease ≥10 mm Hg in diastolic blood pressure after changing from a supine to standing position) was lower in open-label (12.2%) than in double-blind treatment (placebo = 18.2%; cariprazine = 20.2%). Weight gain ≥ 7% was reported in 10.6% of open-label patients, and in 32.3% of placebo-treated patients and 27.0% of cariprazine-treated patients during double-blind treatment. Overall, ophthalmologic testing revealed no evidence of clinically significant lenticular changes. Cataract TEAEs were reported in 1 patient during open-label treatment, and in 1 placebo-and 2 cariprazine-treated patients during doubleblind treatment; confounding factors were present in each case.
Treatment-emergent extrapyramidal symptoms
In open-label treatment, the incidence of rating scale-derived treatment-emergent parkinsonism (SAS score ≤ 3 at baseline and N3 at any postbaseline assessment) and akathisia (BARS score ≤ 2 at baseline and N2 at any postbaseline assessment) was 16.1% and 21.0%, respectively. During double-blind treatment, more placebo-treated than cariprazine-treated patients reported treatment-emergent parkinsonism (8.1% vs 5.0%) and akathisia (10.1% vs 8.0%). Among cariprazineand placebo-treated patients, antiparkinson drugs (for EPS) were used by 19.8% and 19.2%, and propranolol (for akathisia) was used by 10.9% and 8.1%.
Rescue medication
Overall, 193 (25.2%) patients received lorazepam as rescue medication for agitation, irritability, hostility, and restlessness during openlabel treatment, with use decreasing over time (i.e., 22% during the first 2 weeks and 1% by week 6). During double-blind treatment, 8 (8.1%) placebo-and 6 (5.9%) cariprazine-treated patients received rescue medication (lorazepam or oxazepam, in countries where lorazepam is not readily available).
Suicidal ideation and behavior
According to Columbia-Suicide Severity Rating Scale (C-SSRS) (Posner et al., 2011) findings, suicidal ideation was reported in 29 (3.9%) patients during open-label treatment, and in 2 (2.0%) placeboand 1 (1.0%) cariprazine-treated patients during double-blind treatment; most reports were in the least serious categories (wish to be dead; nonspecific suicidal thoughts). Suicidal ideation AEs were reported in 11 patients (1.4%) during open-label treatment (5 events were considered SAEs); no suicidal ideation TEAEs were reported during double-blind treatment. The only report of suicidal behavior occurred during open-label treatment in a patient with a history of suicidal Fig. 3 . Cumulative rate of relapse (double-blind ITT population). The 25th percentile for time to relapse was 92 days in the placebo group and 224 days in the cariprazine group; the 50th percentile (median) was 296 days for the placebo group and it could not be calculated for the cariprazine group because of the low number of relapse events. Between-group separation of the curves did not occur until around day 50. Table 3 Additional efficacy outcomes (ITT populations).
Open-label phase Double-blind phase ideation/prior suicide attempt; the event was an SAE (suicide attempt) and the patient was discontinued from the study.
Discussion
This relapse prevention study examined patients with schizophrenia who completed 20 weeks of open-label cariprazine before randomization to continued treatment with cariprazine or placebo for up to 72 weeks of double-blind treatment. Patients randomized to cariprazine versus placebo had a significantly longer time to relapse and significantly lower rates of relapse (24.8% vs 47.5%). The hazard of relapse for cariprazine-treated patients was less than half that for placebo-treated patients. Mean scores on additional efficacy measures improved during open-label cariprazine treatment, and a clearer trend of symptom worsening was seen in patients randomized to placebo compared with cariprazine during double-blind treatment.
To provide context for these results, estimated relapse rates in a meta-analysis evaluating 1-year relapse in schizophrenia were 27% and 64% for antipsychotic drugs and placebo, respectively (Leucht et al., 2012) ; the analyses included both oral and depot agents, and depot preparations reduced relapse more than did oral drugs. Although comparing relapse rates among antipsychotic agents is difficult due to a lack of consensus about what constitutes relapse in schizophrenia (Kane, 2007) , the time to relapse for placebo-treated patients in our study appears to be longer than in other relapse studies. For example, in several schizophrenia relapse prevention trials, patients switching from antipsychotic to placebo had relapse rates of~15%-30% during the first 4 weeks of double-blind treatment, with separation between treatment groups typically occurring within 2-3 weeks of randomization (Arato et al., 2002; Beasley et al., 2003; Kane et al., 2011; Pigott et al., 2003) . Conversely, only 3% of placebo patients relapsed during the first 4 weeks of double-blind treatment in our study, suggesting that some residual treatment effect may have persisted after cariprazine was discontinued. Between-group separation of the curves did not occur until around day 50 and the 25th percentile for time to relapse was 92 days in the placebo group. Low rates of relapse in the first month after discontinuation of cariprazine may be related to its longer half-life relative to other antipsychotics, which almost all have a plasma half-life of 1 to 2 days (Taylor, 2009) . In contrast, while the calculated effective half-life for cariprazine and desmethyl-cariprazine was approximately 2 days, it was considerably longer for the didesmethylcariprazine metabolite (8.4 days) and the total active moieties (1 week) (Nakamura et al., 2016) .
Although relapse can be decreased by uninterrupted pharmacotherapy (Kane, 2007) , the majority of patients with schizophrenia are at least partially nonadherent to medication (Leucht and Heres, 2006) . Since tolerability issues contribute to medication nonadherence (Leucht and Heres, 2006) , it is important to note that cariprazine was generally well tolerated in this long-term study, with the vast majority of AEs considered mild to moderate in severity. SAEs and AEs that led to discontinuation were most commonly associated with worsening of the underlying psychiatric condition. Akathisia, the most commonly reported TEAE in open-label treatment, was mild or moderate in the vast majority of patients during the study; it accounted for discontinuation of only 1% of patients in open-label treatment and no patients in doubleblind treatment.
Limitations of the study include the lack of an active comparator and the low number of open-label completers. The low completion rate during the open-label phase was largely due to the high rates of withdrawal of consent and the requirement that patients meet stringent efficacy criteria to progress through open-label treatment. Withdrawal of consent was the most common reason for early discontinuation, and follow-up revealed that many of these patients were unable or unwilling to participate in a trial of this long duration (up to 92 weeks). Additionally, AEs were another common reason for discontinuation; it is worth noting, however, that the most common cause of AE discontinuation was worsening of the underlying psychiatric condition. Insufficient therapeutic response (e.g., lack of improvement) is also categorized as a reason for discontinuation, although it is not considered an AE. In this vein, worsening of schizophrenia can reasonably be considered as an event that reflects a lack of response as opposed to a lack of tolerability. Although high open-label dropout was generally not due to tolerability issues, it may affect the ability to generalize these results. As is common in relapse prevention studies, the double-blind population had already been stabilized on cariprazine; as such, patients with unacceptable AEs or tolerability problems during open-label treatment were not part of the double-blind analyses and the double-blind AE profile should be interpreted with caution.
Conclusion
In this relapse prevention study in patients with schizophrenia, the time to relapse was significantly longer and rates of relapse were significantly lower for cariprazine versus placebo. The hazard of relapse for cariprazine-treated patients was calculated to be less than half that for placebo-treated patients. Mean scores on additional efficacy parameters suggested symptom improvement for patients taking open-label cariprazine, and less worsening of symptoms for double-blind cariprazine-treated patients than for placebo-treated patients. The long-term safety profile was consistent with that observed in previous cariprazine clinical trials. Results from this trial suggest that cariprazine may be useful in delaying or preventing relapse in schizophrenia.
Supplementary data to this article can be found online at http://dx. doi.org/10.1016/j.schres.2016.06.030.
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